Is the PFS benefit sufficient to adopt up front acalabrutinib plus BR for all patients with MCL?

In my opinion, PFS is not sufficient to adopt BR-acala as a universal treatment, but this can be an important treatment option for many patients. I would offer the BR-acala combo in patients who value maximizing duration of treatment response, recognizing this is a continuous regimen. On the other h...

As above, the magnitude of benefit is significant, but not "massive" (HR 0.73, 27% reduction in disease progression or death); and long-term BTK can mean a very long duration of immunosuppressive therapy without a break for these patients. I therefore prefer to target this approach to higher-risk pa...

The short answer is no. The ECHO data supports acalabrutinib plus BR as a reasonable, now guideline-preferred option for the specific population studied, but they do not justify blanket adoption for all patients with MCL. The benefit was a real but moderate PFS gain confined to older, transplant-ine...